leon nanodrugs raises $20.2 mln
Leon nanodrugs GmbH said Monday it closed a Series A round of preferred stock at 18.5 million Euros (US$20.2 mln) led by TVM Capital Life Science. Signet Healthcare Partners (USA), LifeCare Partners (Switzerland), CD-Venture (Germany), Albany Private Equity Holding (Australia), and a non-disclosed Family Office from Germany also participated. Munich-based leon nanodrugs is a nanotechnology-based drug development company. The company said another 3 million Euros investment is expected later this year.
27 July 2015•4 mins read
